Head & Neck Cancer

Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.

Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.

Data from a new study show the importance of taking preventative measures against contracting human papillomavirus, including urging patients to get the HPV vaccine.

Researchers compared the swallowing-related quality-of-life scores of patients with oropharyngeal squamous cell carcinoma who received radiotherapy and patients who received transoral robotic surgery with neck dissection.

A new study looked at what methods were used to detect recurrences of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma to see if surveillance guidelines recommended by the National Comprehensive Cancer Center were effective.

Researchers surveyed patients who underwent surgery for thyroid cancer and found a high number reported voice abnormalities post-operation.

Potential new developments have been made in detecting sentinel lymph nodes for patients with localized oral cancers.

The FDA approved pembrolizumab for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.

The phase III KEYNOTE-048 study compared pembrolizumab plus chemotherapy vs the EXTREME regimen in patients with recurrent/metastatic head and neck cancer.

Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.

Erin McMenamin, CRNP, of Penn Medicine, discusses how oral side effects affect head and neck cancer patients.

Survivors of oropharyngeal cancers who developed late lower cranial neuropathy reported having worse treatment-related symptoms.

For patients undergoing primary treatment for head and neck cancer, sexuality was significantly impacted in many patients both prior to and during cancer treatment.

The CoGAPS gene activity algorithm may elucidate molecular changes that occur as H&N tumors acquire resistance to cetuximab, says a Johns Hopkins team.

A Washington University School of Medicine team’s findings might inform future research into inhibitors of angiogenesis and PD-1 in head and neck cancer.

A California study showed women are significantly undertreated for head and neck cancer, with several factors possibly accounting for the disparity.

In a CYCORE trial, mobile technology improved patient tracking, enabling clinicians to detect concerning symptoms early and respond quicker.

AZD1775, a small-molecule, WEE1-targeting TKI, significantly shrunk tumors when administered in combination with cisplatin and docetaxel in a phase I trial.

A phase II trial found that the immune checkpoint inhibitor durvalumab has promising clinical activity and is well tolerated both as monotherapy and in combination with tremelimumab in patients with heavily pretreated recurrent or metastatic head and neck cancer, whose tumors are PD-L1 low or negative.

An early phase trial found that it is feasible to combine nivolumab immunotherapy with radiation therapy and chemotherapy in patients with newly diagnosed local-regionally advanced head and neck cancers.

Patients with human papillomavirus–associated head and neck cancers who respond well to induction therapy can receive substantially lower doses of radiation and still achieve good safety and efficacy outcomes, according to a new phase II trial.

Patients with head and neck cancer who had depressive symptoms at the time of treatment planning had worse overall 2-year mortality.

Researchers have identified mutations that may help distinguish which laryngeal cancer patients could benefit from therapy, since the disease is notoriously resistant to chemotherapeutic treatments.

The staging of oropharyngeal squamous cell carcinoma has undergone key changes in the eighth edition of the American Joint Committee on Cancer Staging Manual, set to take effect January 1, 2018. We describe the revised staging parameters and the rationale in support of the changes.

Results from a study of patients with newly diagnosed head and neck cancer indicate that cognitive screening should be incorporated into pretreatment assessment for patients in order to improve outcomes.